Recent studies have shown that precocious puberty with hyperandrogenism is another clinical feature of patients with MDS and MeCP2 mutations [8–10], suggesting that MeCP2 may play an important role in androgen synthesis. This evidence concerns the gene MECP2 and myelodysplastic syndrome.